Claims for Patent: 10,532,993

Summary for Patent: 10,532,993

Title:	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Abstract:	Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Inventor(s):	deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Davis, CA)
Assignee:	Aerie Pharmaceuticals, Inc. (Bedminster, NJ)
Application Number:	16/138,837
Patent Claims:	1. A method of treating an eye disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a compound of formula (I): ##STR00063## or a pharmaceutically acceptable salt thereof; wherein R.sub.1 and R.sub.2 are, independently, hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4carbonyl, or C.sub.1-C.sub.4carboxyl; or R.sub.1 and R.sub.2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R.sub.1 and R.sub.3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms; wherein one of R.sub.3 and R.sub.4 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C.sub.1-C.sub.8 alkenyl, and the other of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-C.sub.4 alkyl; and wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, halogen, C.sub.1-C.sub.4alkyl, C.sub.2-C.sub.4 alkenyl, amino, nitro, or cyano. 2. The method of claim 1, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl. 3. The method of claim 1, wherein the eye disease comprises glaucoma. 4. The method of claim 1, wherein the eye disease comprises a neurodegenerative eye disease. 5. The method of claim 1, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier. 6. The method of claim 5, wherein the pharmaceutically acceptable carrier is saline buffered to a pH of about 5.5 to about 6.5. 7. The method of claim 5, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl. 8. The method of claim 5, wherein the eye disease comprises glaucoma. 9. The method of claim 5, wherein the eye disease comprises a neurodegenerative eye disease. 10. A method of modulating kinase activity in a cell, comprising contacting the cell with a composition in an amount effective to modulate kinase activity, wherein the composition comprises a compound of formula (I): ##STR00064## or a pharmaceutically acceptable salt thereof; wherein R.sub.1 and R.sub.2 are, independently, hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4carbonyl, or C.sub.1-C.sub.4 carboxyl; or R.sub.1 and R.sub.2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R.sub.1 and R.sub.3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms; wherein one of R.sub.3 and R.sub.4 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C.sub.1-C.sub.8 alkenyl, and the other of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-C.sub.4 alkyl; and wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, halogen, C.sub.1-C.sub.4alkyl, C.sub.2-C.sub.4 alkenyl, amino, nitro, or cyano. 11. The method of claim 10, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl. 12. The method of claim 10, wherein the cell is in a subject. 13. The method of claim 10, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier. 14. The method of claim 13, wherein the pharmaceutically acceptable carrier is saline buffered to a pH of about 5.5 to about 6.5. 15. The method of claim 13, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl. 16. The method of claim 13, wherein the cell is in a subject. 17. A method of reducing intraocular pressure in a subject in need thereof, comprising administering an effective amount of a composition to an eye of the subject, wherein the composition comprises a compound of formula (I): ##STR00065## or a pharmaceutically acceptable salt thereof; wherein R.sub.1 and R.sub.2 are, independently, hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4carbonyl, or C.sub.1-C.sub.4 carboxyl; or R.sub.1 and R.sub.2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R.sub.1 and R.sub.3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms; wherein one of R.sub.3 and R.sub.4 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C.sub.1-C.sub.8 alkenyl, and the other of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-C.sub.4 alkyl; and wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, halogen, C.sub.1-C.sub.4alkyl, C.sub.2-C.sub.4 alkenyl, amino, nitro, or cyano. 18. The method of claim 17, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl. 19. The method of claim 17, wherein the subject suffers from glaucoma. 20. The method of claim 17, wherein the subject suffers from a neurodegenerative eye disease. 21. The method of claim 17, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier. 22. The method of claim 21, wherein the pharmaceutically acceptable carrier is saline buffered to a pH of about 5.5 to about 6.5. 23. The method of claim 21, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl. 24. The method of claim 21, wherein the subject suffers from glaucoma. 25. The method of claim 21, wherein the subject suffers from a neurodegenerative eye disease.